Does rehabilitation help SMA type I?

Yes, and especially — in combination with disease-modifying therapy (nusinersen, Zolgensma, risdiplam). The drugs restore motor neuron function, but without targeted exercise and physiotherapy a correct movement pattern is not formed, and contractures and respiratory problems remain. The modern approach is therefore drug + regular rehabilitation, and outcomes in SMA type I children today are radically different from those of 10 years ago.

Can it be combined with nusinersen?

Not only can — but should. Rehabilitation and drugs are two layers of one strategy, they work in parallel. We receive a discharge note from the treating neurologist with the nusinersen / onasemnogene / risdiplam administration protocol, align the rehabilitation course load with injection or infusion schedules, and coordinate any changes in condition. There is no conflict between the methods.

What is the prognosis for type III?

SMA type III (Kugelberg-Welander disease) is the mildest of the classic forms. Onset after 18 months, ambulation usually preserved in childhood but gradually lost by adolescence or adulthood. With modern therapy and regular rehabilitation ambulation can be preserved much longer, sometimes lifelong. The program goal is to maintain mobility, prevent scoliosis and contractures, and train the respiratory muscles.

SMA

Treatment of SMA in Huizhou

SMA rehabilitation at NeuroLife Huizhou is about maintaining motor function, respiratory musculature, and quality of life in parallel with modern drug therapy (nusinersen Spinraza, onasemnogene Zolgensma, risdiplam Evrysdi). The program combines specialized therapeutic exercise, physiotherapy, breathing gymnastics, and traditional Chinese medicine approaches to support immunity — frequent infections remain the main risk factor in types I–II.

Стабилизация и сдвиг по моторным шкалам

improvement

—

patients

2–3 months

course

Стабилизация и сдвиг по моторным шкалам

improvement

About the condition

What is Spinal Muscular Atrophy (SMA)?

Spinal muscular atrophy (SMA) is an autosomal recessive hereditary disease that damages motor neurons in the anterior horns of the spinal cord. The underlying cause is a mutation in the SMN1 gene on chromosome 5 (5q13.2) leading to a deficit of the SMN protein critical for motor neuron survival. ICD-10 code G12.0 (SMA type I) with subtypes spanning G12.0–G12.9. Incidence — 1 in 6000–10000 newborns, carrier rate 1 in 50.

SMA is classified by age of onset and maximum achieved motor function: type 0 (prenatal), type I / Werdnig-Hoffmann (onset before 6 months, never sit), type II (6–18 months, sit but do not walk), type III / Kugelberg-Welander (>18 months, walk and then lose function), type IV (adult onset).

Disease-modifying drugs (nusinersen Spinraza, onasemnogene Zolgensma, risdiplam Evrysdi) change the prognosis, but they do not restore already lost motor skills and do not solve problems with contractures, scoliosis, or respiratory failure. Rehabilitation remains critically important, and this is the reason families travel to Huizhou.

At NeuroLife Huizhou the program is built individually around the SMA type and the child's current motor abilities, working in parallel with drug therapy. The course lasts 2–3 months and combines several streams:

Therapeutic exercise — gentle exercises for joint mobility, contracture prevention, and training the movements that remain available;
Breathing gymnastics — diaphragm and intercostal training, effective-cough techniques to prevent aspiration pneumonias (critical in types I–II);
Physiotherapy — maintaining muscle trophism;
Occupational therapy — adapting the home environment and selecting assistive devices (orthoses, support seating);
Traditional Chinese medicine — gentle acupuncture, herbal baths, and individual herbal formulas to support immunity.

The TCM component matters especially here: in children with SMA types I–II recurrent infections remain the main cause of hospitalizations, so immunity support directly affects quality and length of life. Rehabilitation goes not "instead of" but "together with" the core medical team — the workload is coordinated with the treating neurologist and pulmonologist and reviewed over the course of the program.

Causes

Autosomal recessive mutation of the SMN1 gene on chromosome 5 (5q13.2). In 95% of patients — a homozygous deletion of SMN1 exon 7; in the rest — a combination of deletion and point mutation. Phenotype severity is determined by the number of copies of the backup SMN2 gene — the more copies, the milder the course. With a family case, carrier screening is recommended when planning the next pregnancy.

Symptoms

Progressive symmetric proximal muscle weakness, hypotonia (floppy baby in type I), areflexia, tongue fasciculations (a hallmark of type I), motor delay or regression. Cognition and sensation are preserved — an important diagnostic feature. In severe forms — swallowing difficulties, respiratory failure, the typical frog-leg posture with abducted hips and bell-shaped chest.

Diagnostics

The gold standard is genetic testing of SMN1 (exon 7 deletion analysis) and SMN2 copy number determination (for prognosis and gene therapy decisions). Additional steps — EMG (characteristic denervation pattern), nerve conduction (normal), CK level (usually normal or slightly elevated — unlike DMD). For motor function — the CHOP-INTEND scale (for type I) or HFMSE (for II–III). For respiratory issues — spirometry, cough effectiveness assessment.

Prognosis

Disease-modifying drugs have changed the landscape. Without therapy in type I — lethality before age 2 from respiratory complications; with nusinersen or Zolgensma — significant motor improvement and life extension, children start sitting, sometimes standing. In types II–III timely drug therapy plus regular rehabilitation maximally slow progression and preserve function. Early intervention (via newborn screening with a family case) yields the best outcome.

Our approach